NCT01042652Unknown不适用
A Pilot Study With Randomized Controlled Open-label Design to Compare Drug-drug Interaction, Antiretroviral Efficacy and Tolerability of Raltegravir Versus Nevirapine as Anchor Drug in Combination Therapy for Treatment-naive HIV+ Chinese Injection Drug Users on Methadone Maintenance
Centers for Disease Control and Prevention, China1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2011年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- The percentages of patients in both arms who require methadone dose adjustment；The average methadone dose in each arm
研究概览
简要总结
This is a pilot randomized controlled Open-label trial to compare raltegravir and nevirapine as anchor Drug in combined antiretroviral therapy(ART) for ART-naive HIV+ Chinese injection drug users who are also on methadone maintenance therapy. The investigators hypotheses include:
- In raltegravir arm compared with nevirapine arm, fewer patients will require methadone dose adjustment to abate methadone withdrawal symptoms. Also the average methadone dose to achieve adequate serum methadone concentrations in patients on the raltegravir-based regimen will be lower compared to that of patients on the nevirapine-based regimen.
- Clinical outcomes in terms of viral suppression, CD4 recovery and occurrence of opportunistic infections will be comparable in the two arms at 6 months and one year.
- Patients in the raltegravir arm will have a similar or better side effect profile, retention rate, and treatment adherence compared to those in the nevirapine arm.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chinese IDUs with documented HIV-1 infection confirmed by a western blot assay.
- •On stable methadone maintenance therapy at the time of enrollment.
- •Antiretrovial treatment naïve and meeting clinical criteria of the Chinese national guideline to initiate antiretroviral therapy.
- •Patient who is of reproductive potential agrees to use an acceptable method of birth control throughout the study. Acceptable method of birth control is defined as intrauterine device (IUD), diaphragm with spermicide, condoms, or abstinence.
排除标准
- •Patients with allergies to or other contraindications for the selected ARV regimens.
- •Patients with acute HIV infection.
- •Use of concomitant therapy which can potentially interact with methadone and scheduled ARVs.
- •Females who are pregnant, breast-feeding, or planning to get pregnant within the study period and using ineffective or hormonal birth control. (Note: All female patients must have a negative pregnancy test at Treatment Day 1)
- •Any active and clinically significant disease or findings discovered on screening medical history, physical examination and laboratory assessment that are not resolved or stabilized within 30 days before the screening phase of this study.
- •Patients with clinical or laboratory evidence of active liver disease, severe hepatic impairment /dysfunction or cirrhosis or elevated liver enzyme levels. (Note: patients co-infected with chronic hepatitis B or C will be allowed to enter the program if their condition is judged to be clinically stable.)
- •Patient's education level that would interfere with the medical, adherence and withdrawal symptoms evaluation.
研究组 & 干预措施
Nevirapine
Active Comparator
干预措施: Raltegravir (Drug)
Raltegravir
Experimental
干预措施: Raltegravir (Drug)
结局指标
主要结局
The percentages of patients in both arms who require methadone dose adjustment；The average methadone dose in each arm
时间窗: 1 year
次要结局
- Changes in CD4+ T lymphocyte count and viral load at weeks 24 and 48 from baseline, and the documented opportunistic infections during study period.(1.5 year)
- The occurrence of side effects, adherence and retention rates in two treatment arms.(1.5 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pilot Study of a Raltegravir Based NRTI Sparing RegimenAcquired Immune Deficiency SyndromeAIDSHuman Immunodeficiency VirusHIV InfectionsNCT00814879Yale University60
Unknown
4 期
Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug UsersHepatitis CHIV InfectionsNCT01105611St. James's Hospital, Ireland40
已完成
不适用
Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 InfectionAcute HIV InfectionNCT00734344University of Alabama at Birmingham18
已完成
4 期
Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 PatientsHIV-1 InfectionNCT01989910Taipei Veterans General Hospital, Taiwan107
已完成
4 期
Comparison of Tacrolimus Extended-Release (Envarsus XR) to Tacrolimus Immediate-Release in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant RecipientsKidney Transplant RejectionNCT04225988Cedars-Sinai Medical Center20